Intra-Cellular Therapies (ITCI) News Today $126.97 -0.05 (-0.04%) As of 12:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period J.P. Morgan Remains a Buy on Intra-Cellular Therapies (ITCI)January 29 at 11:33 PM | markets.businessinsider.comR Squared Ltd Makes New $205,000 Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)R Squared Ltd purchased a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 2,450 shares of the biopharmaceutical company's stock, valued at approximately $205,000. A number of other laJanuary 29 at 8:09 AM | marketbeat.comMoody Aldrich Partners LLC Sells 27,173 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Moody Aldrich Partners LLC cut its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 29.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 63,931 shares of the biopharmaceuJanuary 29 at 7:10 AM | marketbeat.comSG Americas Securities LLC Buys 8,673 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)SG Americas Securities LLC increased its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 204.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,917 shares ofJanuary 29 at 3:14 AM | marketbeat.comMerit Financial Group LLC Buys New Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Merit Financial Group LLC purchased a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 2,465 shares of the biopharmaceutical company's stock, valued at approximately $206,000.January 27 at 3:18 AM | marketbeat.comWhy Intra-Cellular Therapies (ITCI) Is Skyrocketing NowJanuary 26, 2025 | msn.comStockNews.com Begins Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)January 25, 2025 | americanbankingnews.comWhy Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing NowJanuary 24, 2025 | msn.comCantor Fitzgerald Forecasts ITCI FY2025 EarningsJanuary 24, 2025 | americanbankingnews.comRBC Capital Downgrades Intra-Cellular Therapies (ITCI)January 23, 2025 | msn.comIntra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated at StockNews.comStockNews.com initiated coverage on shares of Intra-Cellular Therapies in a report on Thursday. They issued a "hold" rating on the stock.January 23, 2025 | marketbeat.comIntra-Cellular Therapies (ITCI) was downgraded to a Hold Rating at RBC CapitalJanuary 22, 2025 | markets.businessinsider.comIntra-Cellular Therapies' (ITCI) "Sector Perform" Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reissued a "sector perform" rating and set a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday.January 22, 2025 | marketbeat.comBarlow Wealth Partners Inc. Takes $184,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Barlow Wealth Partners Inc. purchased a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 2,200 shares of the biopharmaceutical compJanuary 22, 2025 | marketbeat.comCantor Fitzgerald Predicts ITCI FY2025 EarningsIntra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Intra-Cellular Therapies in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the biopharmaceutical coJanuary 22, 2025 | marketbeat.comIntra-Cellular Therapies Enters Merger Agreement with Johnson & JohnsonJanuary 21, 2025 | americanbankingnews.comAvanza Fonder AB Invests $254,000 in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Avanza Fonder AB bought a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,043 shares of the biopharmJanuary 20, 2025 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Oak Ridge Investments LLCOak Ridge Investments LLC raised its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 74.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,831 shares of the biopharmaceutical company's stock aJanuary 19, 2025 | marketbeat.comAssenagon Asset Management S.A. Decreases Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Assenagon Asset Management S.A. lowered its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 37.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 146,082 shares of the biopharmaceutical company's stock after selling 86,851 sJanuary 19, 2025 | marketbeat.comJim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’January 18, 2025 | insidermonkey.comJim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’January 18, 2025 | msn.comMarketBeat Week in Review – 01/13 - 01/17 (ITCI)The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rallyJanuary 18, 2025 | marketbeat.comPharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 SalesJanuary 17, 2025 | msn.comIs Johnson & Johnson Stock Set to Reward Long-Term Holders? (ITCI)JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractiveJanuary 17, 2025 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of ShareholdersJanuary 16, 2025 | prnewswire.comIntra-Cellular Therapies (NASDAQ:ITCI) Downgraded by Leerink Partnrs to HoldLeerink Partnrs downgraded Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday.January 15, 2025 | marketbeat.comCantor Fitzgerald Upgrades Intra-Cellular Therapies (NASDAQ:ITCI) to Strong-BuyCantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research note on Tuesday.January 15, 2025 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Stock Rating Lowered by Baird R WBaird R W cut shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday.January 15, 2025 | marketbeat.comHold Rating Reiterated for Intra-Cellular Therapies Amid Johnson & Johnson Acquisition at $132 per ShareJanuary 15, 2025 | markets.businessinsider.comPiper Sandler Downgrades Intra-Cellular Therapies (ITCI)January 15, 2025 | msn.comIntra-Cellular Therapies' (ITCI) Neutral Rating Reiterated at Piper SandlerPiper Sandler reissued a "neutral" rating and issued a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday.January 14, 2025 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Sees Large Volume Increase - Time to Buy?Intra-Cellular Therapies (NASDAQ:ITCI) Sees Unusually-High Trading Volume - Here's WhyJanuary 14, 2025 | marketbeat.comNeedham Downgrades Intra-Cellular Therapies (ITCI)January 14, 2025 | msn.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the thirteen brokerages that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendatJanuary 14, 2025 | marketbeat.comIntra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With OptimismJanuary 13, 2025 | msn.comINTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCIJanuary 13, 2025 | businesswire.comShareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public ShareholdersJanuary 13, 2025 | businesswire.comIntra-Cellular Therapies Stock Is Surging Monday: What's Going On?January 13, 2025 | benzinga.comJohnson & Johnson to acquire Intra-Cellular for $132.00 per share in cashJanuary 13, 2025 | markets.businessinsider.comJohnson & Johnson to Acquire Intra-Cellular in $15 Billion DealJanuary 13, 2025 | wsj.comIntra-Cellular Therapies (NASDAQ:ITCI) Shares Gap Up - Here's What HappenedIntra-Cellular Therapies (NASDAQ:ITCI) Shares Gap Up - What's Next?January 13, 2025 | marketbeat.comJ&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disordersJanuary 13, 2025 | financialpost.comIntra-Cellular Therapies (NASDAQ:ITCI) Receives Hold Rating from Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating and set a $100.00 price objective on shares of Intra-Cellular Therapies in a research note on Monday.January 13, 2025 | marketbeat.comIntra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6BJanuary 13, 2025 | investopedia.comITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to ShareholdersJanuary 13, 2025 | businesswire.comJohnson & Johnson to Acquire Intra-Cellular in $14.6B DealJanuary 13, 2025 | marketwatch.comJohnson & Johnson exploring bid for Intra-Cellular Therapies, Bloomberg reportsJanuary 13, 2025 | markets.businessinsider.comJohnson & Johnson To Buy Intra-Cellular Therapies For $132.00/shr In $14.6 Bln All-cash DealJanuary 13, 2025 | markets.businessinsider.comIntra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?January 13, 2025 | msn.comJ&J to buy Intra-Cellular for $132/share in cashJanuary 13, 2025 | msn.com Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address ITCI Media Mentions By Week ITCI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITCI News Sentiment▼0.640.76▲Average Medical News Sentiment ITCI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITCI Articles This Week▼138▲ITCI Articles Average Week Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TAK News ARGX News BNTX News TEVA News BGNE News SMMT News MRNA News GMAB News VTRS News RDY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITCI) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredDonald Trump is about to free crypto from its chains …On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredHot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapyA revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....Smallcaps Daily | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
